Program
enicepatide
Also written as “Enicepatide” and “CT-388”.
Its studies are mostly in Obesity · Overweight · Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Hoffmann-La Roche.
Furthest: phase 3, since Jan 16, 202610 company-led studies, 7 open or runningNext primary completion: Apr 8, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 107 open or running | phase 3since Jan 16, 2026 | Apr 5, 2021 | Apr 8, 2027phase 1 · NCT07626515 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6640 enicepatide (CT-388)
, phase 3, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Zealand Pharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 5, 2021First study: phase 1 study in Diabetes MellitusFirst studyNCT04838405 · 129 enrolled · Australia, Mexico
- Jul 23, 2024Phase 2 study in ObesityNCT06525935 · 469 enrolled · United States
- Oct 3, 2024Phase 2 study in OverweightNCT06628362 · 447 enrolled · United States, Argentina, Canada and more
- Jan 16, 20262 phase 3 studies in ObesityPhase 3 reachedNCT07351058, NCT07351045
- May 11, 2026Phase 2 study in ObesityNCT07589686 · 486 planned
- Jun 1, 2026Phase 1 study in Healthy ParticipantsNCT07626515 · 36 enrolled · China
- Jun 22, 2026Phase 3 study in ObesityNCT07670416 · 300 planned · China
- Oct 16, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07889648 · 948 planned
- Nov 2, 2026Phase 3 study in OverweightNCT07918846 · 8,200 planned
Ahead
- Apr 8, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07626515
- Nov 12, 2027Primary completion: phase 2 study in ObesityNCT07589686
- Feb 24, 2028Primary completion: phase 3 study in ObesityNCT07670416
- Jul 24, 2028Primary completion: phase 3 study in ObesityNCT07351045
TargetBeta
“The study will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide among participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on o…”study summary, read by Claude · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07918846Overweight | 3 | Not yet recruiting | Mar 20, 2031 | 8,200 |
| NCT07889648Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | Apr 2, 2029 | 948 |
| NCT07670416Obesity · China | 3 | Recruiting | Feb 24, 2028 | 300 |
| NCT07626515Healthy Participants · China | 1 | Active, not recruiting | Apr 8, 2027 | 36 |
| NCT07589686Obesity | 2 | Not yet recruiting | Nov 12, 2027 | 486 |
| NCT07351058Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Aug 7, 2028 | 1,600 |
| NCT07351045Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Jul 24, 2028 | 2,000 |
| NCT06628362Overweight · United States, Argentina, Canada and more | 2 | Completed | May 29, 2026 | 447 |
| NCT06525935Obesity · United States | 2 | Completed | Dec 8, 2025 | 469 |
| NCT04838405Diabetes Mellitus · Australia, Mexico | 1 | Completed | Jun 18, 2024 | 129 |
How it is read
Names in the registry
- “Enicepatide”, 9 entries
- “CT-388”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 6 studies
- Overweight, 1 study
- Diabetes Mellitus, Type 2, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.